Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2000
03/29/2000CN1248441A Apomorphine hydrochloride lozenge and usage thereof
03/29/2000CN1050763C Process for preparing topical medicinal composition capable of enhancing skin penetration
03/29/2000CN1050761C Oral administration liquid for curing acne and preparation process thereof
03/29/2000CN1050759C Medicinal composition for curing hysteromyoma and preparation process
03/29/2000CN1050755C Traditional Chinese medicine for treating bleeding disease and preparation process thereof
03/29/2000CN1050749C Anti-inflammatory analogesic plaster
03/29/2000CN1050748C Preparation process of surface anesthesia film
03/29/2000CA2281418A1 Use of a silicone gum to stabilize ascorbic acid and novel compositions containing these components
03/28/2000US6043390 Useful for the intracellular delivery of polynucleotides; cationic lipids useful in the preparation of liposomes and other lipid vesicles for the delivery of nucleic acids into mammalian cells
03/28/2000US6043281 Aldose reductase inhibitors; treatment or prevention of complications of diabetes
03/28/2000US6043215 Preparation of factor IX
03/28/2000US6043214 Method for producing powder formulation comprising an insulin
03/28/2000US6043094 Therapeutic liposome composition and method
03/28/2000US6043091 Compound of 8 to 30 nucleobases targeted to coding region, 3' or 5'-untranslated region, or start codon of nucleic acid encoding a carbohydrate metabolism enzyme; for antidiabetic agents against non-insulin dependent diabetes
03/28/2000US6042847 Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
03/28/2000US6042846 Resistant to nuclease hydrolysis; efficiency
03/28/2000US6042845 Anti fungal treatment of nails
03/28/2000US6042840 Component of a skin care agent
03/28/2000US6042820 Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
03/28/2000US6042818 Film-building agent useful to protect against infections
03/28/2000US6042811 Containing a particulate drug, a diol/diacid condensate as a dispersing aid and a propellant
03/28/2000US6042809 Administrable compositions and methods for magnetic resonance imaging
03/28/2000US6042579 Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
03/28/2000US6042561 Non-intravascular infusion access device
03/28/2000US6041789 Cigarette substitute device and composition for use therein
03/28/2000CA2180658C Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
03/28/2000CA2173815C Use of a hydrofluorocarbon in an emulsion; composition and emulsion containing such a compound
03/28/2000CA2099273C Pressure sensitive adhesives for transdermal absorption formulations
03/28/2000CA2063862C Topical preparation containing a suspension of solid lipid particles
03/26/2000CA2403011A1 Apparatus for electrical moxibustion using the extract
03/26/2000CA2283350A1 Method of preparing pharmaceutical artemisia extract and apparatus for electrical moxibustion using the extract
03/23/2000WO2000015825A1 Condensed plasmid-liposome complex for transfection
03/23/2000WO2000015766A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
03/23/2000WO2000015763A1 Utilization of nanocells in final culture medium products
03/23/2000WO2000015329A1 Method for producing nanoparticles
03/23/2000WO2000015263A1 Expandible microparticle intracellular delivery system
03/23/2000WO2000015262A1 Dry powder active agent pulmonary delivery
03/23/2000WO2000015261A1 Compositions comprising sympathomimetic amine salts unsuitable for illegal use
03/23/2000WO2000015245A2 Stable liquid formulations of botulinum toxin
03/23/2000WO2000015241A1 Protein solution preparation and method for stabilizing the same
03/23/2000WO2000015232A1 Taurolidine and/or taurultam against infectious ulcer or gastritis
03/23/2000WO2000015224A1 Protein formulations
03/23/2000WO2000015203A2 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
03/23/2000WO2000015200A1 Anti-inflammatory pharmaceutical formulations
03/23/2000WO2000015199A1 Long time drug-sustained release preparation
03/23/2000WO2000015198A1 Orally administered controlled drug delivery system providing temporal and spatial control
03/23/2000WO2000015197A1 Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
03/23/2000WO2000015196A1 Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
03/23/2000WO2000015195A1 Quick release pharmaceutical compositions of drug substances
03/23/2000WO2000015194A1 Calcium phosphate delivery vehicle and adjuvant
03/23/2000WO2000015193A1 Mousse composition
03/23/2000WO2000015192A1 Methods and materials related to bioadhesive contraceptive gels
03/23/2000WO2000015173A1 Method for producing gelatin capsules
03/23/2000WO2000007603A3 End modified thermal responsive hydrogels
03/23/2000WO1999066901A3 Transdermal therapeutic system containing hormones and crystallization inhibitors
03/23/2000WO1999065539A9 Tumescent solution
03/23/2000WO1999065493A9 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
03/23/2000WO1999065316A9 Stabilized mixtures of an iodopropargyl compound and a formaldehyde donor
03/23/2000WO1999055285A3 Dilating and support apparatus with disease inhibitors and methods for use
03/23/2000DE19843027A1 Transdermal therapeutic system used for administration of sex hormones contains neohesperidin dihydrochalcone to inhibit crystallization of active agent
03/23/2000DE19842963A1 Stable aerosol formulations containing two or more bioactives used for pharmaceuticals
03/23/2000DE19842914A1 Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon Test system for the characterization of the compatibility of biologically active substances and polyvinylpyrrolidone
03/23/2000DE19842787A1 Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil
03/23/2000DE19842753A1 Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose
03/23/2000DE19842744A1 Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil
03/23/2000DE19842732A1 Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil
03/23/2000DE19842669A1 Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil
03/23/2000DE19837073A1 Folienförmige Wirkstoffträger Sheet-like drug carriers
03/23/2000CA2344441A1 Expandible microparticle intracellular delivery system
03/23/2000CA2344316A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
03/23/2000CA2343920A1 Aerosolizable particles resistant to hygroscopic growth
03/23/2000CA2343760A1 Orally administered controlled drug delivery system providing temporal and spatial control
03/23/2000CA2343268A1 Protein formulations
03/23/2000CA2342292A1 Condensed plasmid-liposome complex for transfection
03/23/2000CA2342243A1 Stable liquid formulations of botulinum toxin
03/23/2000CA2342207A1 Calcium phosphate delivery vehicle and adjuvant
03/23/2000CA2339354A1 Compositions comprising sympathomimetic amine salts unsuitable for illegal use
03/23/2000CA2281197A1 Active component delivery system comprising a coating structure on which is found a salicylic acid derivative-based composition, and its uses
03/22/2000EP0987549A2 Test composition for determining the compatibility of biologically active materials with polyvinylpyrrolidone
03/22/2000EP0987275A2 Molecules that home to a selected organ or tissue in vivo and methods of identifying same
03/22/2000EP0987222A2 Electrolyzed aqueous solution containing water for injection
03/22/2000EP0987029A1 Use of a catonic polymer for the preparation of a complex with nucleic acid and related compositions
03/22/2000EP0987028A1 Pharmaceutical compositions comprising Hedgehog-Proteins and their use
03/22/2000EP0987023A1 Transition metal complexes of non steroidal anti-inflammatory drugs
03/22/2000EP0987021A1 Slow release compositions containing a zinc compound and vitamin C derivatives
03/22/2000EP0987020A1 Metoprolol composition and processes for manufacturing the same
03/22/2000EP0987011A1 Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its use
03/22/2000EP0987009A1 Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition
03/22/2000EP0987008A2 Emulsifier-free finely dispersed systems of the oil-in-water or water-in-oil type
03/22/2000EP0987005A2 Emulsifier-free finely dispersed systems of the oil-in-water or water-in-oil type
03/22/2000EP0987004A2 Emulsifier-free finely dispersed systems of the oil-in-water or water-in-oil type
03/22/2000EP0987001A2 Emulsifier-free finely dispersed systems of the oil-in-water or water-in-oil type
03/22/2000EP0986636A1 Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
03/22/2000EP0986599A2 Process for the preparation of copolyesters
03/22/2000EP0986596A1 Biodegradable polyester urethanes, method for the production and use thereof
03/22/2000EP0986568A1 Novel class of nucleic acid cationic transfecting agents
03/22/2000EP0986417A1 A transurethral device
03/22/2000EP0986408A1 New medicaments based on polymers composed of methacrylamide-modified gelatin
03/22/2000EP0986404A2 Gene therapy delivery system for targeting to endothelia
03/22/2000EP0986403A1 Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
1 ... 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 ... 2991